Profile
Eric Olson is Chief Business Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. since 2025.
Formerly, Mr. Olson was Chief Business Officer at Stoke Therapeutics, Inc. and Vice President & Head-Business Development at Alnylam Pharmaceuticals, Inc. Education includes undergraduate studies at Connecticut College, graduate studies at New York University, and an MBA from the University of Virginia Darden School of Business.
Eric Olson active positions
| Companies | Position | Start |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 22/09/2025 |
Former positions of Eric Olson
| Companies | Position | End |
|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Eric Olson
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Connecticut College
Connecticut College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Virginia Darden School of Business
University of Virginia Darden School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
- Stock Market
- Insiders
- Eric Olson
















